September 22, 2014 10:49 PM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that a...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

36 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer
Age: 49
Total Annual Compensation: $416.3K
Co-Founder
Age: 59
Total Annual Compensation: $310.0K
Vice President of Drug Development
Age: 53
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Announces Retirement of Dominique Charmot as Chief Scientific Officer, Effective from December 23, 2014

Ardelyx, Inc. announced that Dominique Charmot, Ph.D., the company's Chief Scientific Officer, has announced his retirement from Ardelyx, effective December 23, 2014. Dr. Charmot cited personal reasons for his departure, including his desire to spend more time with his family.

Ardelyx, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Ardelyx, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $9,137,000, income from operations of $2,751,000, income before provision for income taxes of $3,753,000, net income and comprehensive income of $3,753,000 or $0.18 per diluted share compared to the total revenue of $7,291,000, loss from operations of $851,000, loss before provision for income taxes of $855,000, net loss and comprehensive loss of $891,000 or $0.81 per diluted share for the same quarter a year ago. For the six months period, the company reported total revenue of $17,687,000, income from operations of $2,287,000, income before provision for income taxes of $682,000, net income and comprehensive income of $682,000 compared to the total revenue of $13,847,000, loss from operations of $1,261,000, loss before provision for income taxes of $1,290,000, net loss and comprehensive loss of $1,361,000 or $1.27 per diluted share for the same period a year ago.

Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM

Ardelyx, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 02:30 PM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Michael G. Raab, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Advanced Glaucoma Technologies, Inc. United States
Prospex Medical III, Inc. United States
HemoStat Laboratories, Inc. United States
InflammaGen, Inc. United States
Boston Biomedical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.